• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi to collaborate with the Center for Genomic Regulation

Sanofi to collaborate with the Center for Genomic Regulation

March 9, 2012
CenterWatch Staff

The Center for Genomic Regulation (CRG), an international biomedical research institute of excellence supported by the Catalan government and the Spanish Ministry of Science and Innovation, has entered a research collaboration with Sanofi to share research programs using state-of-the-art experimental platforms and computational and bioinformatics approaches, in computational biology, medical genetics and epigenetics, with special emphasis in genetic and rare diseases.

This strategic partnership is based on the cross-fertilization of R&D know-how from both sides, including scientific resources, structures and information, technical equipment and human talent. 

"Research cannot remain distanced from the needs of society. Biology is getting ever closer to medicine and an institute like the Center for Genomic Regulation must ensure that its research has a positive impact on human health and national economies. Yet, we cannot do this alone and we need to collaborate with strategic partners for this purpose,” said Dr. Luis Serrano, director of the Center for Genomic Regulation. “Through this agreement Sanofi will have increased access to globally cutting-edge research and the CRG will be linked to a major company that can ensure the translation of research into real-life solutions for patients." 

The CRG and Sanofi already have initiated a first set of projects to discover innovative therapeutic approaches for infectious diseases, develop novel delivery systems using synthetic biology, decipher disease-relevant cellular trans-differentiation pathways and identify original targets from unexploited genomic transcription mechanisms. These four projects will bring added value to basic research by offering a better understanding of disease for pathologies such as tuberculosis and cancer, and also by helping to develop new therapeutic solutions for their treatment.

"We recognize that in order to deliver on our promise to address patients’ needs, we need to tap into and enable innovation inside and outside our walls. Our new relationship with the CRG demonstrates our commitment to work with partners on conditions with unmet and growing medical needs,” said Dr. Maya Said, Sanofi R&D vice president for strategy, science policy & external innovation. “This collaboration is a multi-disciplinary approach with our internal exploratory unit and a major R&D center in Europe, aimed at accelerating the pace of translating early disruptive science into validated concepts that will lead to health solutions for patients and create added value to the public investment in basic research.” 

Further highly innovative collaborative projects will be selected and launched within the three-year period of the agreement.

The CRG is an international biomedical research institute of excellence, whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity. It is committed to technology transfer and the return of knowledge to society. It has a dedicated technology transfer office and a team of professionals with experience in the biotechnology and pharmaceutical businesses, managing the intellectual property generated in the institute and facilitating its transfer to the companies within the sector as patents and licenses that enable the development of innovative products and services.

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing